Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Alnylam Pharmaceuticals Inc shares valued at $9,630,902 were sold by Greenstreet Yvonne on May 30 ’25. At $304.39 per share, Greenstreet Yvonne sold 31,640 shares. The insider’s holdings dropped to 48,948 shares worth approximately $15.58 million following the completion of this transaction.
Also, Greenstreet Yvonne sold 19,297 shares, netting a total of over 5,904,882 in proceeds. Following the sale of shares at $306.00 each, the insider now holds 48,948 shares.
Before that, Greenstreet Yvonne had added 19,297 shares to its account. In a trade valued at $5,848,824, the Officer bought Alnylam Pharmaceuticals Inc shares for $303.10 each.
As published in their initiating research note from Redburn Atlantic on March 31, 2025, Alnylam Pharmaceuticals Inc [ALNY] has been a Buy and the price target has been revised to $353. Analysts at JP Morgan upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in late March. As of November 12, 2024, Wolfe Research has decreased its “Peer perform” rating to a “an Underperform” for ALNY. Earlier on October 16, 2024, Scotiabank initiated its rating. Their recommendation was “a Sector outperform” for ALNY stock.
Analyzing ALNY Stock Performance
On last trading session,, Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] plunged -1.15% to $318.25. The stock’s lowest price that day was $315.21, but it reached a high of $324.9999 in the same session. During the last five days, there has been a surge of approximately 1.90%. Over the course of the year, Alnylam Pharmaceuticals Inc shares have jumped approximately 42.78%. Shares of the company reached a 52-week high of $326.03 on 06/24/25 and a 52-week low of $205.87 on 04/09/25.
Support And Resistance Levels for Alnylam Pharmaceuticals Inc (ALNY)
According to the 24-hour chart, there is a support level at 313.83, which, if violated, would cause prices to drop to 309.42. In the upper region, resistance lies at 323.83. The next price resistance is at 329.42. RSI (Relative Strength Index) is 64.54 on the 14-day chart, showing neutral technical sentiment.
Is Alnylam Pharmaceuticals Inc subject to short interest?
Stocks of Alnylam Pharmaceuticals Inc saw a sharp steep in short interest on 2025-06-13 dropping by -0.31 million shares to 3.38 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 3.68 million shares. A decline of -9.06% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.72 of the overall float, the days-to-cover ratio (short ratio) decline to 3.72.
Which companies own the most shares of Alnylam Pharmaceuticals Inc (ALNY)?
In terms of Alnylam Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 338 in the next 12 months, up nearly 4.99% from the previous closing price of $321.94. Analysts anticipate Alnylam Pharmaceuticals Inc stock to reach 360 by 2025, with the lowest price target being 310. In spite of this, 20 analysts ranked Alnylam Pharmaceuticals Inc stock as Buy at the end of 2025. On August 16, 2024, Goldman assigned a price target of “a Buy” to the stock and upgraded coverage with a $370.
